

Human C5AR1 Full Length Protein (VLP)

Catalog # C51-H52P4



BIOSYSTEMS
Acro

Application

- Immunization
- FACS
- Elisa

Synonym

C5a-R, CD88, C5ar1, C5a anaphylatoxin chemotactic receptor 1


Source

Human C5AR1 Full Length Protein (VLP) (C51-H52P4) is expressed from human 293 cells (HEK293). It contains AA Asp 2 - Val 350 (Accession # [P21730-1](#)).

Predicted N-terminus: Asp


Molecular Characterization

- **Structure**



Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

- **Synthesis Process**



Virus-like particles (VLPs) are non-infectious structures that mimic the shape of viruses but lack a viral genome. During VLP production in cells systems, VLPs self-assemble into 100-200 nm protein particles, and incorporate transmembrane proteins into a VLP-MP complex, resulting in presentation of the protein on the external surface of the VLP. Their repetitive, multivalent surface display and **strong immunogenicity**, making them an excellent candidate for immunization.

Endotoxin

Less than 1.0 EU per µg by the LAL method / rFC method.

Formulation

The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

Supplied as 0.2 µm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping

This product is supplied and shipped with dry ice, please inquire the shipping cost.

Storage

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- The product **MUST** be stored at -70°C or lower upon receipt;
- -70°C for 12 months under sterile conditions.

ACRO Quality Management System

- [QMS\(ISO, GMP\)](#)
- [Quality Advantages](#)
- [Quality Control Process](#)


*The isotype control of empty/mock VLP (Cat. No. [VLP-N5213](#)) is sold separately and not included in protein, you can follow [the link](#) for product information.

Bioactivity-ELISA



Immobilized Human C5AR1 Full Length Protein (VLP) (Cat. No. C51-H52P4) at 5 µg/mL (100 µL/well) can bind Biosimilar Avdoralimab with a linear range of 0.005-0.313 µg/mL (QC tested).

Identity-DLS



The mean peak Radius of VLP is 60-80 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

Background

The Complement 5a Receptor 1 (CD88), a potent anaphylatoxin receptor driving neutrophil chemotaxis and inflammatory cytokine release. It is a key mediator of tissue damage in ANCA-associated vasculitis and severe COVID-19. Antagonists of C5AR1 aim to dampen acute inflammatory injury while preserving upstream complement defense.

Discounts, Gifts,
and more!



www.acrobiosystems.com



5/9/2026